Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Engage Grants Program

Institut national de la recherche scientifique

$25,000.00

Aptamers and riboswitches as models to help tune NMR-based screening methods to find small molecules that target RNA

EF 2018-19

Résumé
The development of drugs which target RNA is challenging as the difficulty associated with examining*potential drug interactions is compounded by RNAs' instability. Also, it has often been an overlooked drug*target and, as such, drug discovery pipelines are typically not designed to include it. However, it has recently*been shown that non-coding RNA structures regulate bacterial growth, survival and virulence making them a*tempting drug target. NMR based drug screening has become an indispensable tool for pharmaceutical*discovery but is still limited in its application with regards to RNA based systems. NMX Research and*Solutions Inc provides NMR based drug screening services to the biotechnology sector. This project seeks to*develop the skills, knowledge base and infrastructure to allow NMX to expand their service line into RNA*based drug discovery. While NMX has several projects for screening of small fragments that bind proteins,*they do not have the expertise to work with RNA. RNA has a reputation of being a molecule very difficult to*work with due to a number of factors: preparation of pure homogenous RNA molecules and avoiding*degradation being to examples. To engage in screening of small molecules binding RNA, NMX will partner*with Dr. Perreault's laboratory to benefit from his expertise in RNA based research. The laboratory of Dr*Perreault works on riboswitches (RNA-receptors) that bind metabolites and are thus excellent models to fine*tune the methodology required to determine interaction of molecules with RNA. The expansion of NMXs'*NMR based drug screening technology into RNA based targets promises to attract new customers and provide*a more comprehensive service for their existing client base.
Programme
Engage Grants Program
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
533439-2018
Name nom
Perreault, Jonathan
Department département
INRS-Institut Armand-Frappier, Centre
Organization id
56
Institution établissement
Institut national de la recherche scientifique
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2018
Competition year année de concours
2018
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1552
Committee name en
Quebec Internal Decision Committee
Committee name fr
Comité de décision interne pour le Québec
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
5402
Research subject group en
Biochemistry
Research subject group fr
Biochimie
Research subject en
Nucleic acids
Research subject fr
Acides nucléiques
Partie
1
Nb partie
1
Application title
Aptamers and riboswitches as models to help tune NMR-based screening methods to find small molecules that target RNA
Keyword
NSERC
Application summary
The development of drugs which target RNA is challenging as the difficulty associated with examining*potential drug interactions is compounded by RNAs' instability. Also, it has often been an overlooked drug*target and, as such, drug discovery pipelines are typically not designed to include it. However, it has recently*been shown that non-coding RNA structures regulate bacterial growth, survival and virulence making them a*tempting drug target. NMR based drug screening has become an indispensable tool for pharmaceutical*discovery but is still limited in its application with regards to RNA based systems. NMX Research and*Solutions Inc provides NMR based drug screening services to the biotechnology sector. This project seeks to*develop the skills, knowledge base and infrastructure to allow NMX to expand their service line into RNA*based drug discovery. While NMX has several projects for screening of small fragments that bind proteins,*they do not have the expertise to work with RNA. RNA has a reputation of being a molecule very difficult to*work with due to a number of factors: preparation of pure homogenous RNA molecules and avoiding*degradation being to examples. To engage in screening of small molecules binding RNA, NMX will partner*with Dr. Perreault's laboratory to benefit from his expertise in RNA based research. The laboratory of Dr*Perreault works on riboswitches (RNA-receptors) that bind metabolites and are thus excellent models to fine*tune the methodology required to determine interaction of molecules with RNA. The expansion of NMXs'*NMR based drug screening technology into RNA based targets promises to attract new customers and provide*a more comprehensive service for their existing client base.
Institut national de la recherche scientifique - $25,… | Canada Spends